• Braveheart Bio and Hengrui Pharma presented 52-week Phase 2 extension results for HRS/BHB-1893 at AHA Scientific Sessions on November 6, 2026.
• Treatment improved exercise capacity and symptoms in obstructive hypertrophic cardiomyopathy, with sustained reductions in blood-flow obstruction.
• No severe or serious on-treatment adverse events occurred; two patients experienced transient reductions in heart-pumping function and resumed treatment at lower doses.
• Separate exploratory analyses suggested improved heart relaxation and filling in non-obstructive disease while preserving pumping function.
• A planned fixed-dose Phase 2b study, TRUEHEART-HCM, will evaluate treatment in obstructive disease, supported by findings suggesting simplified dosing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Braveheart Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611061515PRIMZONEFULLFEED9872487) on November 06, 2026, and is solely responsible for the information contained therein.